[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:high-grade-b-cell-lymphoma:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"High Grade B-Cell Lymphoma","MS4A1 Gene",11,[8,16,22,28,34,41,48,54,60,66,72],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[12],"Phase 2","RECRUITING","2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.016787Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",[12],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.809747Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[12],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[38],"Phase 3","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[45],"Phase 1","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[45],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[45],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":64,"content_modified":71},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"NOT_YET_RECRUITING","2026-05-29T15:36:40.200627Z",{"nct_id":73,"title":74,"phases":75,"status":76,"updated_at":77,"content_modified":78},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[45],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z"]